The lengthening list of pharma alliances focused on molecular glue degraders has another entry after Novartis signed a deal with Monte Rosa Therapeutics worth up to $2.2 billion. The partnership ...

The two companies have been working on molecular glue degraders. These small drug compounds destabilise proteins by bringing them into proximity with enzymes called E3 ubiquitin ligases that cause ...

a Represents net earnings attributable to AbbVie Inc. Intangible asset impairment primarily reflects partial impairment charges related to the U.S. Imbruvica and CoolSculpting intangible assets ...

Reports Full-Year Diluted EPS of $2.39 on a GAAP Basis, a Decrease of 12.1 Percent; Adjusted Diluted EPS of $10.12, a Decrease of 8.9 Percent; These Results Include an Unfavorable Impact of $1.52 ...

Chromatin, the mix of DNA and protein that houses each cell's genome, is more resilient to aging than previously thought, suggests a study published in the Journal of the American Chemical Society by ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

A visible stimulated Raman scattering microscope with extensive pulse chirping in combination with a deep-learning-based denoiser and Fourier reweighting leads to highly sensitive, label-free ...

Developing greener alternatives for industrial chemicals that have a smaller impact on the environment isn't always ...

Plant molecular biology is the study of the molecular basis of plant life. It is particularly concerned with the processes by which the information encoded in the genome is manifested as ...

After hours: February 3 at 4:46:18 PM EST Loading Chart for GLUE ...

Castlelake, L.P. ("Castlelake"), a global alternative investment manager specializing in asset-based private credit, and Niam Credit, an alternative credit provider in Northern Europe, today ...